Katz R L, Johnson T S, Williamson K D
Anal Quant Cytol Histol. 1985 Sep;7(3):227-35.
Flow cytometrically (FCM) derived DNA and RNA profiles were studied in acridine orange (AO)-stained body cavity fluid (BCF) specimens obtained from 78 patients with various solid tissue and hematologic malignancies. The ploidy (DNA index), RNA content (RNA index), proliferative activity (% S + G2M) and DNA and RNA scattergram patterns were tested "double-blind" against the cytologic scoring of specimens as malignant, benign or reactive. It was determined that expression of an "abnormal" RNA index (greater than or equal to 2.8) and an elevated proliferative activity (% S + G2M greater than or equal to 7.4) was dependent on the presence of malignancy; 21 of 22 specimens having those abnormal indices had DNA aneuploidy and were cytologically scored as positive. The AO FCM sensitivity and specificity for detecting malignant cells (when measured against cytology scoring) were 61% and 90%, respectively, using the "abnormal" RNA index and % S + G2M cut-offs together with the cellular DNA aneuploidy marker. By supplementing the cytologic scoring with AO FCM DNA and RNA features, the sensitivity for detecting malignant cells was 94%, as compared to 72% for cytology alone. Two specimens gave false-positive FCM results: a tuberculous effusion with a tetraploid subpopulation and a reactive mesothelial proliferation that was diploid and negative cytologically. Scoring for malignancy based on the visual pattern of the DNA and RNA FCM scattergrams, while showing good correlation for aneuploid specimens, in some cases failed to identify diploid disease. The results demonstrate the usefulness of FCM DNA and RNA analysis for supplementing cytologic examination of BCF specimens for the purpose of detecting malignant cells.(ABSTRACT TRUNCATED AT 250 WORDS)
对从78例患有各种实体组织和血液系统恶性肿瘤的患者获取的吖啶橙(AO)染色体腔液(BCF)标本进行了流式细胞术(FCM)检测的DNA和RNA图谱研究。对标本的倍性(DNA指数)、RNA含量(RNA指数)、增殖活性(%S + G2M)以及DNA和RNA散点图模式进行“双盲”检测,以对照标本的细胞学评分,判断为恶性、良性或反应性。结果确定,“异常”RNA指数(大于或等于2.8)和增殖活性升高(%S + G2M大于或等于7.4)的表达取决于恶性肿瘤的存在;22个具有这些异常指数的标本中有21个存在DNA非整倍体,细胞学评分呈阳性。使用“异常”RNA指数和%S + G2M临界值以及细胞DNA非整倍体标记物时,AO FCM检测恶性细胞的敏感性和特异性(相对于细胞学评分)分别为61%和90%。通过用AO FCM的DNA和RNA特征补充细胞学评分,检测恶性细胞的敏感性为94%,而单独细胞学检测的敏感性为72%。有两个标本给出了FCM假阳性结果:一个具有四倍体亚群的结核性胸腔积液和一个细胞学呈二倍体且阴性的反应性间皮增生。基于DNA和RNA FCM散点图的视觉模式对恶性肿瘤进行评分,虽然对非整倍体标本显示出良好的相关性,但在某些情况下无法识别二倍体疾病。结果表明,FCM DNA和RNA分析对于补充BCF标本的细胞学检查以检测恶性细胞是有用的。(摘要截短于250字)